A Phase 1, Open-Label, Dose Escalation Study Evaluating the Safety and Tolerability of EZN-2968, a Locked Nucleic Acid Antisense Oligonucleotide Against Hypoxia-Inducible Factor-1α, Administered as a Weekly 2-Hour Intravenous Infusion in Adult Patients With Advanced Solid Tumors or Lymphoma

Inclusion Criteria:

Patients must meet all of the following criteria to be eligible for
enrollment into the study.

- Histologically or cytologically confirmed diagnosis of advanced and/or metastatic
solid tumor or lymphoma (Hodgkin's or non-Hodgkin's)

- Patients who have failed standard therapy and have no known effective therapy
available to them

- Patients may have a tumor amenable to biopsy

- Measurable or evaluable disease.

- Age 18 years or older

Exclusion Criteria: Patients meeting any of the following exclusion criteria will not be
eligible for enrollment.

- Concurrent serious medical illness

- Known, clinically suspected, or history of central nervous system (CNS) tumor
involvement

- Prior chemotherapy, immunotherapy, investigational agent, or other therapy used to
treat the cancer within 4 weeks (6 weeks for prior treatment with mitomycin C or
nitrosoureas) before the scheduled administration of EZN-2968. Luteinizing
hormone-releasing hormone (LHRH) agonist therapy is permitted for patients with
hormone refractory prostate cancer.